Navigation Links
In New Study, Duloxetine Was Equally Effective, Regardless of,Switch Method, in Reducing Painful Symptoms in Ssri Non- or,Partial-responders with Depression

ectively, were:
  • Overall Pain 20.3 percent, 17.9 percent;
  • Headache 25.6 percent, 15.6 percent;
  • Back Pain 18.2 percent, 20.2 percent;
  • Shoulder Pain 17.9 percent, 16.2 percent;
  • Interference with Daily Activities 29.5 percent, 23.2 percent;
  • Time in Pain While Awake 28.8 percent, 26.3 percent.

Efficacy, safety, and tolerability outcomes following direct switch from SSRI to duloxetine were similar to those observed for start-taper switch. Few patients experienced a serious adverse event (5 patients during the 10 weeks of treatment and 1 during the taper period), and there was a low rate of discontinuations due to adverse events (6.6 percent DS vs. 3.8 percent STS).

This was an open-label study, so biases inherent in open-label studies could have been a factor in the observed outcomes. Due to the large number of possible SSRI/dose possibilities for patients entering the study, it was necessary for study investigators to use their clinical judgment to devise an appropriate 2-week down-titration regimen for patients in the STS group. Although general guidance was provided to investigators within the study protocol, the taper was nevertheless not rigidly standardized.

About Duloxetine
While duloxetine’s mechanism of action in humans is not fully known, it is believed to affect both serotonin and norepinephrine/noradrenaline mediated nerve signalling in the brain and the spinal cord. Based on pre-clinical studies, duloxetine is a balanced and potent reuptake inhibitor of serotonin and norepinephrine/noradrenaline. Scientists believe its effect on pain perception is due to increasing the activity of serotonin and norepinephrine in the central nervous system.

Duloxetine is approved for the treatment of depression and diabetic peripheral neuropathic pain in many countries and is approved in some countries for the treatment of stress urinary
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. In New Study, Duloxetine Reduced Non-specific Pain and Emotional Symptoms Associated with Depression
2. Newly Published Data Demonstrates Superiority of Cipralex Over Duloxetine for Acute Treatment of Depression
3. Roxro Pharma’s Novel Intranasal Pain Reliever Effective, Well Tolerated in Phase 3 Study
4. MabThera Significantly Increases Survival of Lymphoma Patients Regardless of Chemotherapy Regimen
5. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
6. Cimzia Effective in Reducing Signs and Symptoms of Rheumatoid Arthritis
7. The Lancet Publishes PREVAIL Study Results Showing Lovenox Superiority Over Unfractionated Heparin for Reducing the Risk of Venous ThromboEmbolism in Patients With Acute Ischemic Stroke
8. The International Myeloma Foundation Says New Clinical Trial Results Could Improve Survival While Reducing Side Effects For Many Patients
9. New Study Confirms Role for Pertussis Immunization of Entire Family in Reducing Infant Pertussis
10. Dharma Therapeutics Shows IDDS Is Effective in Reducing Pain Associated With Insertion of an Intravenous Catheter in Their Phase 2 Clinical Trial
11. Pooled Studies Showed Desvenlafaxine Succinate Significantly Improved Painful Symptoms and Anxious Symptoms Associated with Major Depressive Disorder in Adults, Compared With Placebo
Post Your Comments:
(Date:10/31/2014)... Oct. 31, 2014  Australian biopharmaceutical company Specialised Therapeutics ... (nanoparticle albumin-bound paclitaxel) in combination with gemcitabine, will be ... with metastatic pancreatic cancer from 1 November. ... is the 5 th most common cause of ... cancer deaths, with the lowest 5-year survival of all ...
(Date:10/31/2014)... -- Investor-Edge has initiated coverage on the ... Isis Pharmaceuticals Inc. (NASDAQ: ISIS ), Halozyme ... Inc. (NASDAQ: ACAD ), and Synta Pharmaceuticals ... can be accessed at: http://investor-edge.com/register . ... at 4,566.14, up 0.37%, the Dow Jones Industrial Average ...
(Date:10/31/2014)... Australia and BARCELONA , October ... Ltd (Multigate) was found to infringe two Australian patents of ... for sale in Australia safety IV ... 17.10.14 in Federal Court of Australia ... http://www.austlii.edu.au/au/cases/cth/FCA/2014/1110.html . In the detailed judgment, ...
Breaking Medicine Technology:Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 2Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 3Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 4Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 5Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 6Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 7Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 8Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma 2Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma 3Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma 4Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma 5B. Braun Wins Patent Disputes Against Poly Medicure Ltd's Australian Distributor Multigate Medical Devices Pty. Ltd. and Spanish Distributor Dextromédica S. L. 2
... Beshear announced yesterday that most of Kentucky,s Medicaid program ... $375 million. In modernizing the state,s Medicaid pharmacy benefits, ... pharmacy benefit managers (PBMs) to lower prescription drug costs, ... "Governor Beshear has done the right thing ...
... 8, 2011 Stryker Joint Preservation, a business unit ... American Orthopaedic Society for Sports Medicine meeting that it ... to distribute Stryker,s RegenKit-THT, a one-step system designed for ... (A-PRP) from a small sample of blood at the ...
Cached Medicine Technology:Modernizing Medicaid Rx with 'Innovative' PBM Tools Will Help Kentucky Save $375 Million 2Stryker Announces Exclusive Collaboration With RegenLab 2
(Date:10/31/2014)... TheHardwareCity.com is the place to purchase home ... space heaters are available at the online store. Now, ... 1500w portable electric space heater. , The space heater ... an energy efficient way to heat a small space ... produce 1500 Watts, ensuring a quick warm up period. ...
(Date:10/31/2014)... Prevention Research Center for Healthy Neighborhoods (PRCHN) at ... a key player in nearly $13.32 million in ... Northeast Ohio. , The Centers for Disease Control ... $4.35 million over five years. The funds will ... and disseminating individual, environmental, and policy interventions that ...
(Date:10/31/2014)... Thousand Oaks, CA (PRWEB) October 31, 2014 ... flat tummy also has amazing health effects for ... were created by a Doctor of Science and ... discovered through his dedication to pelvic floor reeducation ... incidence of urinary incontinence, Diastasis Recti, Prolepses, etc. ...
(Date:10/31/2014)... -- Surgery for low back pain caused by spinal ... you live, a new report says. "Nearly 80 ... some point in their lives, and about 30 million ... spine problem," co-author Brook Martin, of the Dartmouth Institute ... college news release. In spinal stenosis, thickening of ...
(Date:10/31/2014)... of four older Americans say that either they or ... treatment, according to the latest issue of The Gerontological ... ( PP&AR ), which goes on to show ... fail to honor patients, end-of-life health care wishes. , ... Issues and Options ," features 12 articles that present ...
Breaking Medicine News(10 mins):Health News:Big Heat 1500w Electric Space Heater Now Available at TheHardwareCity.com 2Health News:Case Western Reserve, Cuyahoga County, YMCA of greater Cleveland: Public health grants 2Health News:Case Western Reserve, Cuyahoga County, YMCA of greater Cleveland: Public health grants 3Health News:Super Models and European Celebrities’ Secret Flat Tummy System Comes to America 2Health News:Super Models and European Celebrities’ Secret Flat Tummy System Comes to America 3Health News:Spinal Surgery Varies by Region in U.S.: Study 2Health News:Advance directives can benefit patients, families, and health care system 2
... potential benefits of human papillomavirus (HPV) vaccinations or frequent HPV ... concludes a new study published online February 15 in the ... found that the rate of new infections preventable by vaccination ... any age typically do not progress to cervical intraepithelial neoplasia ...
... skull bone appear to be a durable treatment option that ... according to a report in the February issue of ... of the JAMA/Archives journals. , Single-sided deafness, also ... percent and 3 percent of children, according to background information ...
... and lungs suffer, study finds , MONDAY, Feb. 15 (HealthDay ... pipes or cigars instead of cigarettes are kidding themselves, a ... means is deleterious," said Dr. R. Graham Barr, assistant professor ... lead author of a report in the Feb. 16 issue ...
... further problems, experts say, , MONDAY, Feb. 15 (HealthDay News) ... are likely to have another stroke soon after the initial ... according to a new study by researchers from the Medical ... importance of recognizing that anyone who has had a stroke ...
... As more people undergo bariatric procedures, use of revisions ... News) -- Repeat weight-loss surgery carries a higher risk ... has found. , The surgical treatment, known as bariatric ... loss in severely obese people. Rates of repeat bariatric ...
... Small study shows patients with ocular type benefit from ... toxin type A (Botox), the drug that can temporarily ... migraines, a small study suggests. , Specifically, Botox may ... as crushing or eye-popping, otherwise known as ocular migraines. ...
Cached Medicine News:Health News:News brief: Benefit of HPV Vaccination, Frequent Screening for Women over 41 is Likely to be Low 2Health News:Bone-anchored hearing aids help youth with single-sided deafness 2Health News:Cigars, Pipes No 'Healthy' Alternative to Cigarettes 2Health News:Cigars, Pipes No 'Healthy' Alternative to Cigarettes 3Health News:After a Stroke, High Risk for a Recurrence 2Health News:After a Stroke, High Risk for a Recurrence 3Health News:Repeated Weight-Loss Surgery Carries Added Risks 2Health News: Botox May Prevent Some Migraines 2Health News: Botox May Prevent Some Migraines 3
Advanced operating microscope with high-resolution apochromatic optics. Senso-servo drive to keep the microscope in perfect balance even if parts are moved or mounted elsewhere....
Opmi Vario/S88 system surgical microscope. It is applicable for neurosurgery, spinal, ENT and P&R surgery....
The Horizontal-Vertical (H/V) lumbar valve system is the only differential pressure valve for lumbo-peritoneal shunting, which addresses orthostatic overdrainage....
Curved left, Hardy Curettes, bayonet, working distance 120 mm, total length 241 mm....
Medicine Products: